Janet B Mcgill

List of Publications by Year
in descending order

54 papers	3,404 citations	279798 23 h-index	182427 51 g-index
54 all docs	54 docs citations	54 times ranked	3558 citing authors

#	Article	IF	Citations
1	Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrology Dialysis Transplantation, 2023, 38, 894-903.	0.7	48
2	Insulin Receptor Autoantibodyâ€“mediated Hypoglycemia in a Woman With Mixed Connective Tissue Disease. Journal of the Endocrine Society, 2022, 6, bvab182.	0.2	2
3	Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations. Diabetes Technology and Therapeutics, 2022, 24, 814-823.	4.4	22
4	Monogenic and syndromic diabetes due to endoplasmic reticulum stress. Journal of Diabetes and Its Complications, 2021, 35, 107618.	2.3	18
5	Understanding inhaled Technosphere Insulin: Results of an early randomized trial in type 1 diabetes mellitus. Journal of Diabetes, 2021, 13, 164-172.	1.8	8
6	Letter to the Editor from McKee and McGill: â€œGlycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoringâ€• Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4298-e4299.	3.6	0
7	Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion. Diabetes Technology and Therapeutics, 2021, 23, 715-725.	4.4	7
8	Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin. JAMA - Journal of the American Medical Association, 2021, 325, 2262.	7.4	182
9	What's Wrong with This Picture? A Critical Review of Current Centers for Medicare & Medicaid Services Coverage Criteria for Continuous Glucose Monitoring. Diabetes Technology and Therapeutics, 2021, 23, 652-660.	4.4	26
10	The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care, 2021, 44, 2729-2737.	8.6	24
11	Update on Biosimilar Insulins: A US Perspective. BioDrugs, 2020, 34, 505-512.	4.6	6
12	Comprehensive Pulmonary Safety Review of Inhaled TechnosphereÂ® Insulin in Patients with Diabetes Mellitus. Clinical Drug Investigation, 2020, 40, 973-983.	2.2	7
13	Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 2397.	7.4	191
14	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England Journal of Medicine, 2020, 382, 2493-2503.	27.0	228
15	Evidenceâ€based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease. Diabetes, Obesity and Metabolism, 2020, 22, 1014-1023.	4.4	5
16	Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness. Diabetology and Metabolic Syndrome, 2019, 11, 61.	2.7	15
17	Biologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network. Journal of Diabetes and Its Complications, 2019, 33, 107400.	2.3	4
18	Optimizing Postprandial Glucose Management in Adults With Insulin-Requiring Diabetes: Report and Recommendations. Journal of the Endocrine Society, 2019, 3, 1942-1957.	0.2	16

#	Article	IF	Citations
19	Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. American Journal of Medicine, 2019, 132, S49-S57.e5.	1.5	11
20	Culinary Medicine: Advancing a Framework for Healthier Eating to Improve Chronic Disease Management and Prevention. Clinical Therapeutics, 2019, 41, 2184-2198.	2.5	30
21	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 2019, 21, 1199-1208.	4.4	83
22	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinolâ€"Rationale, Design, and Baseline Data. Diabetes Care, 2019, 42, 1454-1463.	8.6	39
23	Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. American Journal of Cardiology, 2019, 124, S45-S52.	1.6	62
24	Visual Field Loss in Patients With Diabetes in the Absence of Clinically-Detectable Vascular Retinopathy in a Nationally Representative Survey. , 2019, 60, 4711.		14
25	High prevalence of comorbid autoimmune diseases in adults with type 1 diabetes from the HealthFacts database. Journal of Diabetes, 2019, 11, 273-279.	1.8	29
26	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2019, 73, 309-315.	1.9	18
27	Mistaken Identity: Missed Diagnosis of Type 1 Diabetes in an Older Adult. Medical Research Archives, 2019, 7, .	0.2	2
28	Effect of a Shoulder Movement Intervention on Joint Mobility, Pain, and Disability in People With Diabetes: A Randomized Controlled Trial. Physical Therapy, 2018, 98, 745-753.	2.4	11
29	High prevalence of systemic rheumatic diseases in women with type 1 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 737-739.	2.3	4
30	Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections. JAMA - Journal of the American Medical Association, 2017, 317, 371.	7.4	834
31	ESRD After Heart Failure, Myocardial Infarction, or Stroke in TypeÂ2 Diabetic Patients With CKD. American Journal of Kidney Diseases, 2017, 70, 522-531.	1.9	15
32	Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. Annals of Internal Medicine, 2017, 167, 365.	3.9	385
33	Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 700-708.	11.4	99
34	Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.8	13
35	Moyamoya syndrome causing stroke in young women with type 1 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 1640-1642.	2.3	10
36	Diabetic Kidney Disease. Missouri Medicine, 2016, 113, 390-394.	0.3	9

#	Article	IF	Citations
37	Type 2 diabetes, obesity, and sex difference affect the fate of glucose in the human heart. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H1510-H1516.	3.2	31
38	Relationship Between Skin Intrinsic Fluorescenceâ€"an Indicator of Advanced Glycation End Productsâ€"and Upper Extremity Impairments in Individuals With Diabetes Mellitus. Physical Therapy, 2015, 95, 1111-1119.	2.4	19
39	Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-NaÃ¯ve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents. Diabetes Care, 2015, 38, 2274-2281.	8.6	30
40	Safety and Efficacy of Hyperglycemia Urgency Order Set. Journal of Diabetes Science and Technology, 2014, 8, 1062-1063.	2.2	0
41	Anti-Diabetes Therapy: Safety Considerations for Patients With Impaired Kidney Function. Postgraduate Medicine, 2014, 126, 161-171.	2.0	2
42	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. BMJ Open Diabetes Research and Care, 2014, 2, e000011.	2.8	31
43	The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review. Diabetes Therapy, 2014, 5, 43-63.	2.5	40
44	Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment. Diabetes Care, 2013, 36, 237-244.	8.6	162
45	Pharmacotherapy in Type 2 Diabetes: A Functional Schema for Drug Classification. Current Diabetes Reviews, 2012, 8, 257-267.	1.3	18
46	Potentiation of abnormalities in myocardial metabolism with the development of diabetes in women with obesity and insulin resistance. Journal of Nuclear Cardiology, 2011, 18, 421-429.	2.1	38
47	Impact of Incretin Therapy on Islet Dysfunction: An Underlying Defect in the Pathophysiology of Type 2 Diabetes. Postgraduate Medicine, 2009, 121, 46-58.	2.0	15
48	Progress and Controversies: Treating Obesity and Insulin Resistance in the Context of Hypertension. Journal of Clinical Hypertension, 2009, 11, 36-41.	2.0	22
49	Selecting among ADA/EASD tier 1 and tier 2 treatment options. Journal of Family Practice, 2009, 58, S26-34.	0.2	1
50	Clinical safety of the selective PKC-Î² inhibitor, ruboxistaurin. Expert Opinion on Drug Safety, 2006, 5, 835-845.	2.4	42
51	Anemia and the role of erythropoietin in diabetes. Journal of Diabetes and Its Complications, 2006, 20, 262-272.	2.3	69
52	Circulating 1,5-Anhydroglucitol Levels in Adult Patients With Diabetes Reflect Longitudinal Changes of Glycemia: A U.S. trial of the GlycoMark assay. Diabetes Care, 2004, 27, 1859-1865.	8.6	126
53	Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes: A randomized, parallel-group, 24-week study. Diabetes Care, 2003, 26, 2598-2603.	8.6	235
54	Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clinical Cardiology, 2001, 24, 66-72.	1.8	46